

Notizen

Synthesis of Purine and Pyrimidine Substituted Nitroxides

R. Marcus, P. N. Preston, and J. S. Suffolk

Chemistry Department, Heriot-Watt University, Edinburgh

(Z. Naturforsch. **31 c**, 101–102 [1976]; received July 8/September 24, 1975)

Purines, Pyrimidines, Nitroxides

Reaction of 6-hydrazinopurine and 2-hydrazinopyrimidine with 2,2,6,6-tetramethylpiperidone-1-oxyl gives 2,2,6,6-tetramethylpiperidone-1-oxyl-(6-purinyl)hydrazone (**3b**) and 2,2,6,6-tetramethylpiperidone-1-oxyl-(2-pyrimidinyl)hydrazone (**4b**) respectively. Compound **3b** is inactive even at high dose levels against TLX/5 lymphoma and **3b** and **4b** are both inactive in tests using the L1210 leukaemia system.


Considerable effort has been expended by Brown *et al.*¹ on the synthesis of purine N-oxides for evaluation in chemotherapy and oncogenesis assays. Recently they adduced chemical evidence² suggesting the intermediacy of a radical-anion in one solution decomposition mode of esters of the potent oncogen³ 3-hydroxyxanthine. It is therefore desirable to synthesise and assay if possible free radicals bearing purinyl or pyrimidinyl substituents. Recently 3-hydroxyxanthine-derived radicals (**1**, **2**) have been generated⁴ but cannot be isolated. We now report our preliminary studies on the synthesis and assay of stable nitroxide radicals containing purine and pyrimidine substituents.

Treatment of 6-hydrazinopurine⁵ (**3a**) or 2-hydrazinopyrimidine⁶ (**4a**) with 2,2,6,6-tetramethylpiperidone-1-oxyl⁷ (**5a**) gave the desired free radicals⁸ **3b** and **4b** as stable pale yellow and beige solids respectively. Approaches to nitroxides using the lithium derivative **4c** were less successful: when the free radical **5a** was allowed to react⁹ with the lithium derivative **4c**¹⁰, only the hydroxylamine derivative **5b** was isolated. Treatment¹¹ of *tert*-butyl phenyl nitron with the lithium derivative **4c** followed by autoxidation of the ensuing anion resulted in a nitroxide **4d** as evidenced by ESR spectroscopy ($a_N = 1.46$; $a_H = 0.34$ mT) although no attempt was made to isolate this free radical.

Antitumor Evaluation

The purine derivative **3b** was tested on TLX/5 lymphoma, but was found to be inactive even at high dose levels (288 mg/kg for 5 days). Compounds **3b** and **4b** were also inactive in tests using the L1210 leukaemia system.

Requests for reprints should be sent to Dr. P. N. Preston, Department of Chemistry, Heriot-Watt University, Riccarton, Currie, Edinburgh EH14 4AS.



Experimental Section

2,2,6,6-Tetramethylpiperidone-1-oxyl-(6-purinyl)-hydrazone **3b**

To a saturated solution of 6-hydrazinopurine⁵ (0.45 g, 3 mmol) in a mixture of glacial acetic acid (1.6 ml) and water (11 ml) was added 2,2,6,6-tetramethylpiperidone-1-oxyl⁷ (0.5 g, 3 mmol). The mixture was shaken for 15 min, cooled and extracted with chloroform. The extract was washed with water, dried (MgSO₄) and evaporated to give a solid that was chromatographed (silica gel with CHCl₃/EtOH 9:1 eluant) to give a pure pale yellow product (0.60 g, 66%), m. p. 207–208 °C (dec.). Found: C, 55.49; H, 6.62; N, 32.51%. C₁₄H₂₀N₇O requires: C, 55.61; H, 6.67; N, 32.43%. IR (KBr) 3200, 2965, 2922, 1622, 1326 cm⁻¹. UV λ_{max}^{EtOH} 298 (ε, 2.7 × 10⁴), 224 (1.7 × 10⁴). ESR. triplet, $a_N = 1.425$ mT (in benzene).

2,2,6,6-Tetramethylpiperidone-1-oxyl-(2-pyrimidinyl)hydrazone (**4b**)

To a solution of 2-hydrazinopyrimidine⁶ (1.8 g, 16 mmol) in a mixture of glacial acetic acid (0.3 ml) and water (2.2 ml) was added 2,2,6,6-tetramethylpiperidone-1-oxyl⁷ (1.5 g, 9 mmol) and the mixture

shaken for 20 min. The product was extracted with ether and the ensuing solid was purified by preparative scale tlc ($\text{CHCl}_3 : \text{Et}_2\text{O}$ 1 : 1 eluant with silica gel). The orange extract was washed with ether to give a pure product (1.6 g, 30%) m.p. 114–115 °C. Found: C, 59.25; H, 7.54; N, 26.49%. $\text{C}_{13}\text{H}_{20}\text{N}_5\text{O}$ requires C, 59.52; H, 7.68; N, 26.70%.

IR (KBr) 3210, 2965, 2922, 1585, 1342, 1228 cm^{-1} . UV $\lambda_{\text{max}}^{\text{EtOH}}$ 264 nm (ϵ 2.3×10^4). ESR triplet, $a_N = 1.50$ mT (in benzene).

We thank the Science Research Council for a research grant and Professor A. B. Foster for helpful comments. We also thank Dr. O. C. Yodor and Dr. T. A. Connors for biological assay data.

¹ G. B. Brown, *Prog. Nucleic Acid Res.* **8**, 209 [1968].

² N. J. M. Birdsall, J. C. Parham, V. Wölcke, and G. B. Brown, *Tetrahedron* **28**, 3 [1972].

³ M. N. Teller, G. Stohr, and H. Dienst, *Cancer Res.* **30**, 179 [1970]; K. Sugiura, M. N. Teller, J. C. Parham, and G. B. Brown, *Cancer Res.* **30**, 184 [1970].

⁴ J. C. Parham, I. Pullman, and G. B. Brown, *Tetrahedron* **29**, 3329 [1973].

⁵ J. A. Montgomery and L. B. Holum, *J. Amer. Chem. Soc.* **79**, 2185 [1957].

⁶ V. Vanderhaeghe and M. Claesen, *Bull. Soc. Chim. Belges* **68**, 30 [1959].

⁷ E. G. Rozantsev, *Free Nitroxyl Radicals*, p. 213, Plenum Press, New York 1970.

⁸ *cf.* The synthesis of a spin labelled dinucleotide: W. E. Trommer, H. Wenzel, and G. Pfeleiderer, *Liebigs Ann. Chem.* **1974**, 1357.

⁹ *cf.* ref. 7, p. 64.

¹⁰ J. C. Roberts, *J. Chem. Soc.* **1952**, 3065.

¹¹ *cf.* E. G. Janzen and B. J. Blackburn, *J. Amer. Chem. Soc.* **91**, 4481 [1969].